- 期刊
A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma
延伸閱讀
- Abulaizi, M., Tomonaga, T., Satoh, M., Sogawa, K., Matsushita, K., Kodera, Y., Obul, J., Takano, S., Yoshitomi, H., Miyazaki, M., & Nomura, F. (2011). The Application of a Three-Step Proteome Analysis for Identification of New Biomarkers of Pancreatic Cancer. International Journal of Proteomics, 2011(), 172-184. https://doi.org/10.1155/2011/628787
- 李燕鳴（2012）。Accurate Use of Serum Prostate Specific Antigen in Detection of Early Prostate Cancer。台灣老年醫學暨老年學雜誌，7(4)，209-216。https://doi.org/10.29461/TGG.201211.0001
- Jiang, H., Du, C., Cai, M., He, H., Chen, C., Qiu, J., & Wu, H. (2013). An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma. HPB Surgery, 2013(), 26-32. https://doi.org/10.1155/2013/298726
- Huang, W. H., Wu, W. W., Wang, H. H., Lin, T. Y., & Cheng, K. S. (2003). Duodenal Adenocarcinoma with Liver Metastasis and Elevated Serum Alpha-fetoprotein. Mid-Taiwan Journal of Medicine, 8(3), 169-173. https://doi.org/10.6558/MTJM.2003.8(3).8
- Alemar, B., Gregório, C., & Prolla, P. A. (2015). miRNAs As Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review. Biomarker Insights, 2015(), 113-124. https://doi.org/10.4137/BMI.S27679